CDK4 and neoplasm: An association between Rb loss of function and resistance to combined CDK4/6i and ET was also observed in 3 patients with ER+/HER2− ABC who received CDK4/6i (palbociclib or ribociclib) and showed somatic mutations in Rb in circulating tumor DNA (ctDNA) upon disease progression [17].